Pipeline Insight: Hematological Malignancies - Pursuit for the next blockbuster intensifies

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-03-30

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and Datamonitor's insight into their clinical and commercial potential is provided.


Scope

  • Research and analysis of the hematological malignancies pipeline with in-depth clinical and commercial assessment of Phase III candidates
  • Seven major pharmaceutical market sales forecasts to 2016 for key pipeline candidates incorporating product specific assumptions and events
  • Segmentation and examination of product pipeline by developmental phase, class, indication and developer
  • Insight and analysis of the hematological malignancies market potential including commercial opportunity and disease epidemiology


    • Report Highlights
    180 different pipeline candidates have been identified of which 22 are in late-phase development. These existing candidates have a forecast sales potential of up to $3.61 billion in the seven major pharmaceutical markets by 2016.

    Agents holding strong commercial potential include Novartis' Gleevec-follow-on, Tasigna (nilotinib), and Genzyme's already approved purine analog Clolar (clofarabine) which is in development for acute myeloid leukemia. Other notable candidates include the anti-idiotype therapeutic vaccines and Biogen Idec's anti-CD23 MAb, lumiliximab.

    Over 50% of the products are being investigated in acute and/or chronic leukemia. However, as an individual hematological subtype, NHL attracts the greatest attention from developers with 53 (29%) products in the pipeline despite the malignancy being comparatively well served by existing treatment regimens.


    Reasons to Purchase

  • Acquire a detailed appreciation and impartial perspective of the entire hematological malignancies developmental pipeline
  • Identify the key products in late-phase development based on sales forecasts to 2016 and Datamonitor's drug assessment methodology
  • Consider, assess and react to opportunities and risks influencing the future potential of products in the hematological malignancies pipeline

    • Table of Contents

    Other users found this report page using the following search terms: hematological cancer lymphoma leukemia

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.